Greenwich LifeSciences, Inc. (NASDAQ:GLSI)
| Market Cap | $219.29M+82.2% |
| Revenue (ttm) | $0 |
| Net Income | -$21.68M-24.0% |
| EPS | -$1.54-13.2% |
| Shares Out | 14.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,710 |
| Open | $15.40 |
| Previous Close | $15.28 |
| Day's Range | $14.59 - $15.40 |
| 52-Week Range | $7.78 - $34.10 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | $50.00(+234.67%) |
| Earnings Date | Nov 13, 2026 |
About GLSI
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
$GLSI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GLSI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GLSI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GLSI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New GLSI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GLSI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GLSI
| VTIVanguard Morningstar Total Stock Market ETF | $3.59M |
| IWMiShares Russell 2000 ETF | $3.20M |
| VXFVanguard Extended Market ETF | $1.49M |
| IWOiShares Russell 2000 Growth ETF | $1.18M |
| VTWOVanguard Russell 2000 ETF | $821.83K |
| VFMOVanguard U.S. Momentum Factor ETF | $689.82K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GLSI’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
No Form 4 filings in the last 90 days.